Helen Giamarellou - Selected Publications#


1) Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2 producing Klebsiella pneumoniae. Souli M, Karaiskos I, Masgala A, Galani L, Barmpouti E, Giamarellou H.Eur J Clin Microbiol Infect Dis. 2017;49(4):482. (the last peer-reviewed publication)
Impact Factor 2.857 Number of Citations 4

2) Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase producing gram negative bacteria. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H.Int J Antimicrob Agents.2014;43(1):52-9
Impact Factor 4.097 Number of Citations 79

3) Multi-drug resistant and extensively drug resistant Gram negative pathogens: current and emerging therapeutic approaches. Karaiskos I, Giamarellou H. Expert Opin Pharmacother. 2014;15(10):1351-70 (review)
Impact Factor 3.543 Number of Citations 69

4) Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Kontopidou F, Giamarellou H, Katerelos P, Maragos A, Kioumis I, Trikka-Graphakos E, Valakis C, Maltezou HC; Group for the Study of KPC-producing Klebsiella pneumoniae infections in intensive care units. Clin Microbiol Infect. 2014;20(2):O117-23
Impact Factor 4.575 Number of Citations 59

5) Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Karaiskos I, Galani L, Baziaka F, Giamarellou H. Int J Antimicrob Agents. 2013;41(6:)499-508. (Review)
Impact Factor 4.097 Number of Citations 36

6) Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Karvanen M, Plachouras D, Friberg LE, Paramythiotou E, Papadomichelakis E, Karaiskos I, Tsangaris I, Armaganidis A, Cars O, Giamarellou H. Antimicrob Agents Chemother. 2013;57(1):668-71
Impact Factor 4.415 Number of Citations 38

7) Metallo-β-lactamases: a last frontier for β-lactams? Cornaglia G, Giamarellou H, Rossolini GM. Lancet Infect Dis. 2011;1(5):381-93 (review)
Impact Factor 21.372 Number of Citations 325

8) An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T, Vourli S, Zerva L, Armaganidis A, Kanellakopoulou K, Giamarellou H. Clin Infect Dis. 2010; 1;50(3):364-73.
Impact Factor 8.880 Number of Citations 180

9) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. Antimicrob Agents Chemother. 2009;53(8):3430-6
Impact Factor 4.415 Number of Citations 287

10) Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster.
Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I, Papadomichelakis E, Kopterides P, Souli M, Armaganidis A, Giamarellou H. J Antimicrob Chemother. 2007;59(4):786-90
Impact Factor 5.093 Number of Citations 135

Imprint Privacy policy « This page (revision-4) was last updated on Monday, 28. August 2017, 10:18 by System
  • operated by